Claims for Patent: 11,779,552

Summary for Patent: 11,779,552

Title:	Method of treating cancer using selective estrogen receptor modulators
Abstract:	Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.
Inventor(s):	Suzanne E. Wardell, Erik R. Nelson, Donald P McDonnell
Assignee:	Duke University
Application Number:	US17/558,731
Patent Claims:	1. A method of treating an estrogen receptor positive breast cancer in a subject, wherein the estrogen receptor positive breast cancer is resistant to one or more aromatase inhibitors, the method comprising administering to a subject a compound, (R)-6-{2-{ethyl[4-(2-ethylaminoethyl)benzyl]amino}-4-methoxyphenyll-5,6,7,8-tetrahydronaphthalen-2-ol, which has the structure 2. The method of claim 1, wherein the compound is administered as part of a pharmaceutical composition. 3. The method of claim 2, wherein the composition is administered daily as a single dose. 4. The method of claim 2, wherein the composition is administered daily as a multi-dose. 5. The method of claim 1, wherein the one or more aromatase inhibitor(s) is selected from the group consisting of anastrozole, letrozole, exemestane, formestane, fadrozole, aminoglutethimide, testolactone, and combinations thereof. 6. The method of claim 5, wherein the one or more aromatase inhibitor(s) is selected from anastrozole, letrozole, exemestane, and combinations thereof. 7. The method of claim 1, wherein an effective amount of the compound is administered. 8. The method of claim 7, wherein the effective amount is from about 200 mg/day to about 500 mg/day. 9. The method of claim 8, wherein the effective amount is about 400 mg/day. 10. The method of claim 7, wherein the compound is administered by oral administration, intravenous administration, intradermal injection, intramuscular injection or subcutaneous injection. 11. The method of claim 10, wherein the compound is administered by oral administration. 12. The method of claim 1, further comprising administering an effective amount of at least one compound selected from the group consisting of a cyclin-dependent kinase 4 and 6 inhibitor (CDK4/6 inhibitor), an antiestrogen, a ligand of retinoic acid or retinoxic X receptor, an antiprogestin, an antiandrogen, vitamin D or metabolite thereof, a farnesyl transferase inhibitor, a PPARa or gamma agonist and a MAP kinase inhibitor. 13. The method of claim 12, wherein the at least one compound is a CDK4/6 inhibitor. 14. The method of claim 12, wherein the at least one compound is an antiestrogen.